Santo Sandhu, an investment advisor with Wolverton Securities, said he believes the best opportunities right now lie in biotechnology.
That has led him to BioMark Diagnostics Inc., a Richmond B.C. company that is developing a cancer diagnostic system, using a known drug, which has already been approved by the U.S. Federal Drug Administration and Health Canada.
With phase 3 clinical trials under way in Bangladesh and Manitoba, Canada, the company has seen its stock price jump to $1.02 from 44 cents in early November.
Read more at http://www.stockhouse.com